Get the latest NAV of Tata India Pharma & Healthcare Fund Direct Growth. View historical returns compared to its benchmark and category average. Know which stocks and sectors the fund is investing in. Get an estimate of returns from the SIP and lump sum returns calculator. View detailed holding analysis and peer comparison. Get INDmoney ranking of the fund.
₹34.75
▲0.1%1D
NAV as on 27 Jun 2025
13.96%/per year
Since Inception
▲▼
2624 people have invested ₹ 1.4Cr in Tata India Pharma & Healthcare Fund Direct Growth in the last three months
Fund returns vs Benchmark returns vs Category Average returns as on (27-Jun-25)
The fund has consistently outperformed the benchmark (Nifty 500) over the last 1Y, 3Y, 5Y time periods.
Powered by IND quant engine
IND ranking is not available for this fund.
Calculate SIP and lumpsum returns based on historical performance
Total Investment
0
Profit
Total Corpus
0
See fund asset allocation details as on (14-Jun-25)
Fund Distribution
as on (14-Jun-25)
Equity 90.8%
Debt & Cash 9.2%
See fund sector allocation details as on (14-Jun-25)
Sector Allocation
Equity 90.8%
Debt & Cash 9.2%
Top 2 Sectors in May were Health, Basic Materials
Health
97%
Basic Materials
3%
Health
98%
Basic Materials
2%
as on (31-May-25)
Equity
Get key fund statistics, minimum investment details, AUM, expense ratio, exit load, and tax treatment.
Expense ratio | 0.63% |
Benchmark | Nifty Pharma TR INR |
AUM | ₹1232 Cr |
Inception Date | 28 December, 2015 |
Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 0.2% |
Lock In | No Lock-in |
TurnOver | 28.44% |
STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
Risk | Very High Risk |
Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.
Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.96% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 15.92%, 26.37% and 23.12% respectively.
Tata India Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Apollo Hospitals Enterprise Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Divi's Laboratories Ltd
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Tata India Pharma & Healthcare Fund Direct Growth has no lock in period.
Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021
5Y CAGR
▲ 35.44
5Y CAGR
▲ 31.70
5Y CAGR
▲ 24.18
5Y CAGR
▲ 28.49
3Y CAGR
▲ 27.59
Tata India Pharma & Healthcare Fund
VS
Nippon India Pharma Fund Direct Growth